3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
17
Brain Neoplasms
5
Neoplasm Metastasis
4
Neoplasms
3
Meningeal Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Pathologic Complete Response
1
Multiple Myeloma
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Breast Cancer
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anatomic Stage IA Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
Temozolomide
2
Sodium Chloride
2
Dexmedetomidine
2
tucatinib
1
tipifarnib
1
sagopilone
1
pembrolizumab
1
Trastuzumab
1
Tissue Banks
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Radiation
1
Dasatinib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Central Nervous System Diseases
×
tucatinib
×
Clear all
NCT04512261
2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2
Withdrawn